These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?". Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL Clin Pharmacokinet; 2020 Feb; 59(2):269-271. PubMed ID: 31802401 [No Abstract] [Full Text] [Related]
16. The French Levothyrox Mouly S; Roustit M; Bagheri H; Perault-Pochat MC; Molimard M; Bordet R Therapie; 2019 Jun; 74(3):431-435. PubMed ID: 30737052 [No Abstract] [Full Text] [Related]
17. Reply to the letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by S. Montenegro, C. Helwig, J.-E. Schwarze, C. Castello-Bridoux, S. Marque, M. Lispi, et al. (J Gynecol Obstet Hum Reprod. 2023;52(8):102640). Barriere P; Arbo E; Jenkins J J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102644. PubMed ID: 37573940 [No Abstract] [Full Text] [Related]
19. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110 [TBL] [Abstract][Full Text] [Related]
20. Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL Clin Pharmacokinet; 2020 Jan; 59(1):1-5. PubMed ID: 31432471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]